Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.

Department of Hematology Catholic University of Leuven Leuven Belgium

Erasmus Medical Center Rotterdam the Netherlands

Fundação Champalimaud Lisbon Portugal

Hospital Clinic de Barcelona Barcelona Spain

Karolinska Institutet Stockholm Sweden

Leeds Institute of Cancer and Pathology University of Leeds Leeds UK

Università di Torino Azienda Ospedaliera San Giovanni Torino taly

Universitätsklinikum Heidelberg Heidelberg Germany

University Athens School of Medicine Athens Greece

University Hospital Hôtel Dieu Nantes France

University Hospital Hurriez Lille France

University of Navarra Navarra Spain

University of Ostrava Ostrava Czech Republic

University of Salamanca Salamanca Spain

University of Wurzburg Wurzburg Germany

Wilhelminen Cancer Research Institute Wilhelminen Austria

Haematologica. 2019 Dec;104(12):2335-2336. doi: 10.3324/haematol.2019.228676. PubMed

Zobrazit více v PubMed

Franssen LE, Mutis T, Lokhorst HM, van de Donk NWCJ. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol. 2019;10:2040620718822660. PubMed PMC

Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017;130(24):2594–2602. PubMed PMC

Shah NN, Maatman T, Hari P, Johnson B. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Front Oncol. 2019;9:146. PubMed PMC

Laâbi Y, Gras MP, Carbonnel F, et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J. 1992;11(11):3897–3904. PubMed PMC

Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Anti-BCMA antibodies in the future management of multiple myeloma. Expert Rev Anticancer Ther. 2019;19(4):319–326. PubMed

Cohen AD. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma. Clin Adv Hematol Oncol. 2018;16(12): 804–806. PubMed

Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13): 1688–1700. PubMed PMC

Raje NS, Berdeja JG, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–1737. PubMed PMC

Zhao WH, Liu J, Wang BY, et al. Updated analysis of a phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B-Cell maturation antigen, in patients with relapsed/refractory multiple myeloma. Blood. 2018;132(Suppl 1):955. PubMed PMC

Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4): 625–638. PubMed

Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112–116. PubMed PMC